CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Short Interest Update

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) was the recipient of a large decline in short interest in the month of March. As of March 31st, there was short interest totalling 342,200 shares, a decline of 59.4% from the March 15th total of 843,600 shares. Based on an average daily trading volume, of 841,800 shares, the days-to-cover ratio is currently 0.4 days. Approximately 14.0% of the shares of the company are short sold.

Institutional Trading of CERo Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Avantax Planning Partners Inc. boosted its holdings in CERo Therapeutics by 89.9% during the fourth quarter. Avantax Planning Partners Inc. now owns 2,585,151 shares of the company’s stock valued at $155,000 after purchasing an additional 1,224,021 shares in the last quarter. Parallel Advisors LLC bought a new position in shares of CERo Therapeutics during the 1st quarter worth approximately $161,000. Finally, ARCH Venture Management LLC boosted its stake in CERo Therapeutics by 550.4% in the 4th quarter. ARCH Venture Management LLC now owns 9,393,561 shares of the company’s stock valued at $564,000 after buying an additional 7,949,265 shares in the last quarter. Institutional investors own 29.64% of the company’s stock.

CERo Therapeutics Stock Performance

Shares of CERO stock opened at $0.67 on Tuesday. The firm has a fifty day moving average of $1.26 and a 200-day moving average of $6.45. CERo Therapeutics has a 52-week low of $0.64 and a 52-week high of $184.99.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.